Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

Havrdova E, Cohen JA, Horakova D, Kovarova I, Meluzinova E

Therapeutics and Clinical Risk Management 2017, 13:1423-1437

Published Date: 16 October 2017